So we believe that efficiency of this combination must be researched with controlled and extensive studies.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:As of today, there is yet no succesful treatment of chronic hepatitis B.
📊
Key Findings & Data:Failure of interferon a-2a treatment for chronic viral hepatitis has prompted combination therapy.
💡
Conclusion & Impact:So we believe that efficiency of this combination must be researched with controlled and extensive studies.
🔬Design:Article
📍Scope:Comprehensive Sample
⚙️Variables:Chronic hepatitis B · interferon -2a · lamivudine
Abstract
As of today, there is yet no succesful treatment of chronic hepatitis B. Failure of interferon a-2a treatment for chronic viral hepatitis has prompted combination therapy. We present a 4 year old male infected with chronic hepatitis B in the replication phase who was treated with a combination of interferon a-2a and lamivudine therapy. Full remission was reached at the end of one year and this affect was still observed after one months of follow-up. So we believe that efficiency of this combination must be researched with controlled and extensive studies.
Sönmez, F., Ünüvar, T., İnan, G., Türkmen, M., Öztürk, A., Dikicioğlu, E. (2002). Interferon and Lamivudine Combination Therapy in a Child with Chronic Hepatitis B: ACase Report. Meandros Medical And Dental Journal, Volume: 3 Issue: 3. https://ajindex.com/articles/1291434
Çakaloðlu Y, Ökten A. Kronik viral hepatitlerde tedavi yaklaþýmlarý 1998Ankara Bilimsel TýpYayýnevi Sayfa: 26-51.
Pessoa MG, Wright TL. Update on clinical trials in the treatment of hepatitis B. J Gastroenterol Hepatol 1999;14 Suppl: 6-11.
Schalm SW, Heathcote J, Cianciara J et al. Lamivudin and alpha interferon combination treatment of patients with chronic hepatitis B infection:a randomised trial. Gut 2000;46: 562-8.
Farrel G. Hepatitis B antigen seroconversion effects of lamivudine alone or in combination with interferon alpha. J Med Virol 2000;6: 374-9.
Mutimer D, Naoumov Nhonkoop P et al. Combination alpha-interferon and lamivudine therapy for alphainterferon-rezistant chronic hepatitis B infection: results of a pilot study. J.Hepatol 1998;28: 923-9.
Wong DKH, Cheung AM, O'Rourke K, et al. Effect of alpha interferon treatment in patients with hepatitis B antigen positive chronic hepatitis B. A meta analysis. Ann Intern Med 1993;119: 312-323.
Wong JB, Koff RS, Tine F, Pauker SG. Costeffectiveness of interferon-á 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122: 664-675.
Janssen HL, Gerken G, Carreno V et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999;30: 238-43.
Lau DT, Everhart C, Kleiner DE et al. Long-term Follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 1660-7.
Rumi M, Romeo R, de Filippi F et al. A multicentre randomized clinical trial of recombinant alpha-2a interferon therapy in patients with chronic hepatitis B. Ital J Gastroenterol 1993;2:117-20.
Dusheiko G, Lamivudine of chronic hepatitis B. Rev Med Virol 1998;8: 153-159.
Dienstag Jl,Schiff ER,Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341: 1256-63.
Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
Dusheiko G, Lamivudine of chronic hepatitis B. Rev Med Virol 1998;8: 153-159.
Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.